Search

[EN] Among strontium-based drugs, the Strontium ranelate (SrR) is a divalent strontium salt of ranelic acid which has an overall effect over the bone microarchitecture improvement. However, some findings reveal that the SrR affects in an opposite manner to the cell proliferation and osteoblastic differentiation, based on its concentration. Consequently, its release should be controlled. The incorporation of Halloysite nanotubes (HNT) as nanocarriers of SrR, into gelatine (GN) coatings, tailors the release of this anabolic bone-forming and anti-catabolic agent to stimulate bone growth. In fact, as-prepared GN/HNT-SrR coatings release 100 % SrR in phosphate buffered saline (PBS) within 21 days, and cellular studies of the nanocomposite coatings (MTT, Alkaline Phosphatase activity (ALP) and Calcium deposition assay) confirm the valuable bio-performance of these composite coatings to enhanced bone regeneration. In the present manuscript, suspensions with HNT/GN weight ratio of 0.5 are formulated to coat AISI 316 L stainless steel foils by Electrophoretic Deposition (EPD). Zeta potential determination is used to stablish the drug loading (HNT-SrR) by electrostatic interaction, as well as to optimize the dispersion of bare HNT and HNT SrR-loaded in a GN aqueous solution. Polyethilenimnine (PEI) is used as stabilizer to buffer the suspension media, assure cargo-drug dispersion and sequential release, while the thermal gelling of the suspension controls and step up the coating formation during EPD.